Premenopausal serum androgens and breast cancer risk: a nested case-control study
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Introduction: Prospective epidemiologic studies have consistently shown that levels of circulating androgens in postmenopausal women are positively associated with breast cancer risk. However, data in premenopausal women are limited. Methods: A case-control study nested within the New York University Women's Health Study was conducted. A total of 356 cases (276 invasive and 80 in situ) and 683 individually-matched controls were included. Matching variables included age and date, phase, and day of menstrual cycle at blood donation. Testosterone, androstenedione, dehydroandrosterone sulfate (DHEAS) and sex hormone-binding globulin (SHBG) were measured using direct immunoassays. Free testosterone was calculated. Results: Premenopausal serum testosterone and free testosterone concentrations were positively associated with breast cancer risk. In models adjusted for known risk factors of breast cancer, the odds ratios for increasing quintiles of testosterone were 1.0 (reference), 1.5 (95% confidence interval (CI), 0.9 to 2.3), 1.2 (95% CI, 0.7 to 1.9), 1.4 (95% CI, 0.9 to 2.3) and 1.8 (95% CI, 1.1 to 2.9; Ptrend = 0.04), and for free testosterone were 1.0 (reference), 1.2 (95% CI, 0.7 to 1.8), 1.5 (95% CI, 0.9 to 2.3), 1.5 (95% CI, 0.9 to 2.3), and 1.8 (95% CI, 1.1 to 2.8, Ptrend = 0.01). A marginally significant positive association was observed with androstenedione (P = 0.07), but no association with DHEAS or SHBG. Results were consistent in analyses stratified by tumor type (invasive, in situ), estrogen receptor status, age at blood donation, and menopausal status at diagnosis. Intra-class correlation coefficients for samples collected from 0.8 to 5.3 years apart (median 2 years) in 138 cases and 268 controls were greater than 0.7 for all biomarkers except for androstenedione (0.57 in controls). Conclusions: Premenopausal concentrations of testosterone and free testosterone are associated with breast cancer risk. Testosterone and free testosterone measurements are also highly reliable (that is, a single measurement is reflective of a woman's average level over time). Results from other prospective studies are consistent with our results. The impact of including testosterone or free testosterone in breast cancer risk prediction models for women between the ages of 40 and 50 years should be assessed. Improving risk prediction models for this age group could help decision making regarding both screening and chemoprevention of breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C., & Mulvihill, J. J. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.24.1879 · Cited by 3,334 · cited 1×
“If results in premenopausal women are confirmed, androgens could be considered for inclusion in breast cancer risk prediction models, such as the Gail model [18].”
BackgroundScreening for breast cancer: U.S. Preventive Services Task Force recommendation statement
Siu, A. L., & on behalf of the U.S. Preventive Services Task Force (2016) · Annals of Internal Medicine · doi:10.7326/m15-2886 · Cited by 2,094
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 1×
“A weakness of our study is that we used radioimmunassays without an extraction step, and the sensitivity and specificity of such assays have been questioned [46,62].”
MethodBody mass index, serum sex hormones, and breast cancer risk in postmenopausal women
Endogenous Hormones Breast Cancer Collaborative Group (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg022 · Cited by 1,093
Burger, H. G., Dudley, E. C., Cui, J., Dennerstein, L., & Hopper, J. L. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6740 · Cited by 439 · cited 1×
“We also observed a high temporal reliability of total testosterone and free testosterone over a median time of two years, as was also reported by others [36,37].”
ResultRothman, M. S., Carlson, N. E., Xu, M., Wang, C., Swerdloff, R., Lee, P., Goh, V. H. H., Ridgway, E. C., & Wierman, M. E. (2011) · Steroids · doi:10.1016/j.steroids.2010.10.010 · Cited by 248
Zhou, J., Ng, S., Adesanya-Famuiya, O., Anderson, K., & Bondy, C. A. (2000) · The FASEB Journal · doi:10.1096/fj.99-0863com · Cited by 193 · cited 2×
“Results from experimental studies, though, have been inconsistent, with some studies [25,26] reporting an inhibitory effect of androgens on estrogen-induced breast cell proliferation, while others did not [27].”
BackgroundResultEndogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women
Key, T. J. (2011) · Steroids · doi:10.1016/j.steroids.2011.02.029 · Cited by 89 · cited 1×
“Notwithstanding these differences, the main mechanism proposed to explain the increase in risk observed among postmenopausal women is the aromatization of androgens into estrogens in peripheral adipose tissue [50].”
Background
Cited by
Obesity and cancer risk: Emerging biological mechanisms and perspectives
Avgerinos, K. I., Spyrou, N., Mantzoros, C. S., & Dalamaga, M. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.001 · Cited by 1,567
(2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70301-2 · Cited by 399
Androgen therapy in women: a reappraisal: an Endocrine Society Clinical Practice Guideline
Wierman, M. E., Arlt, W., Basson, R., Davis, S. R., Miller, K. K., Murad, M. H., Rosner, W., & Santoro, N. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2260 · Cited by 363
Pathology of triple negative breast cancer
Borri, F., & Granaglia, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.005 · Cited by 300
Metadata
- Authors
- Zeleniuch-Jacquotte, A., Afanasyeva, Y., Kaaks, R., Rinaldi, S., Scarmo, S., Liu, M., Arslan, A. A., Toniolo, P., Shore, R. E., & Koenig, K. L.
- Venue
- Breast Cancer Research
- Published
- 2012-02-16
- Volume
- 14
- Issue
- 1
- Pages
- R32-R32
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W2133100322
- Cited by
- 56
- References
- 8
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.